Bone-growth drugs may increase jaw disease risk | Science News



Support credible science journalism.

Subscribe to Science News today.


Bone-growth drugs may increase jaw disease risk

New study finds link between common drug and jawbone death

5:36pm, January 2, 2009

Some drugs meant to build bone for people with osteoporosis could increase the risk of developing a devastating jaw infection, a new study suggests. Even short-term use of some osteoporosis drugs may raise the risk of the jaw disease, called osteonecrosis. The results appear January 1 in the Journal of the American Dental Association.

Drugs called bisphosphonates — which include the widely prescribed alendronate (Fosamax), ibandronate (Boniva) and risedronate (Actonel) — are taken orally and commonly prescribed to combat osteoporosis, a disease that is marked by weak bones and affects over 10 million people in the United States.

Jawbone disease is “absolutely rare, and one of the least likely bones to get infected,” says study coauthor Parish Sedghizadeh, a dentist and researcher at the University of Southern California in Los Angeles. Over the last several years, Sedghizadeh and other dentists at the University of Southern Calif

This article is available only to subscribing members. Join the Society today or Log in.

Get Science News headlines by e-mail.

More from Science News

From the Nature Index Paid Content